# A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus in India

Study · id `cardio:ct-nct05659537` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05659537](<https://clinicaltrials.gov/study/NCT05659537>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05659537

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 212 participants.

## Technical summary

Registry record NCT05659537. Allocation not applicable; no masking; primary purpose treatment. Start 2022-12-29 (actual); primary completion 2024-01-16 (actual). Results posted on 2025-02-05.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 212 participants (enrolled count; ClinicalTrials.gov record NCT05659537, source copy `cardio:ctgov-nct05659537-2025-02-20`, retrieved 2026-10-26)
- Started: 2022-12-29 (actual) (ClinicalTrials.gov record NCT05659537, source copy `cardio:ctgov-nct05659537-2025-02-20`, retrieved 2026-10-26)
- Primary completion: 2024-01-16 (actual) (ClinicalTrials.gov record NCT05659537, source copy `cardio:ctgov-nct05659537-2025-02-20`, retrieved 2026-10-26)
- Completion: 2024-01-16 (actual) (ClinicalTrials.gov record NCT05659537, source copy `cardio:ctgov-nct05659537-2025-02-20`, retrieved 2026-10-26)
- Results first posted: 2025-02-05 (ClinicalTrials.gov record NCT05659537, source copy `cardio:ctgov-nct05659537-2025-02-20`, retrieved 2026-10-26)
- Countries: India (ClinicalTrials.gov record NCT05659537, source copy `cardio:ctgov-nct05659537-2025-02-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05659537-2025-02-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus in India
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Dulaglutide
- Lead sponsor: Eli Lilly and Company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Eli Lilly and Company (`cardio:eli-lilly`)

## Provenance

Content hash: 0dbfb13abe8d6d7110e1459c0a57dd18f2c14cb9426171f4ff4471908eb969d0
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
